亚盛医药
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325 2021-07-29 07:40
Ascentage Pharma's MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma, Marking the Twelfth Obtained by the Company 2021-07-21 18:37
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax 2021-07-19 18:41
Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling US$245 Million Including Commercialization of Olverembatinib (HQP1351) in China, Joint Clinical Development of Lisaftoclax (APG-2575) and Equity Investment 2021-07-15 01:43
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors 2021-06-15 07:39
Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL 2021-06-08 07:30
Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs 2021-06-08 07:21
ASCO 2021 | Ascentage Pharma to Announce Updated Data of Lisaftoclax (APG-2575) Demonstrating an ORR of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in Oral Presentation 2021-05-20 08:44
ASCO 2021 | Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation 2021-05-20 08:17
Ascentage Pharma (6855.HK) Becomes a Constituent of MSCI China Small Cap Index 2021-05-13 08:28
Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Released in Oral Presentations for the First Time 2021-04-21 08:38
Ascentage Pharma Releases Preclinical Data of Its Core Drug Candidates at AACR Annual Meeting 2021, with Results Signifying the Potential of Multiple Combination Therapies in Cancer 2021-04-13 08:28
Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director 2021-04-02 19:39
Ascentage Pharma Announces 2020 Annual Results and Reports Launch Readiness for Its Core Drug Candidate 2021-03-31 23:27
Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115 2021-03-26 08:38
Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation 2021-03-24 19:07
Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021 2021-03-11 08:35
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer 2021-02-02 17:24
Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company 2021-01-29 08:29
Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference 2021-01-14 09:32
1 4 5 6 7 8